证券代码：688189 证券简称：南新制药 公告编号：2020-011 湖南南新制药股份有限公司 关于参加湖南辖区上市公司 2020 年度投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步做好投资者关系管理工作，加强与投资者的互动交流，使广大投资 者能更深入全面地了解公司情况，湖南南新制药股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会与深 圳市全景网络有限公司联合举办的"湖南辖区上市公司 2020 年度投资者网上集 体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net） 参与本次网上投资者接待日活动。本次活动时间为 2020 年 9 月 11 日（星期五） 下午 15:00—17:00。届时公司董事会秘书、证券事务代表将通过网络在线交流 形式和投资者进行沟通与交流。欢迎广大投资者积极参与。 特此公告。 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2020, representing a year-on-year increase of 15%[13]. - The net profit for the same period was 100 million CNY, with a profit margin of 20%[13]. - The company's operating revenue for the first half of 2020 was approximately RMB 580.56 million, representing a year-on-year increase of 27.77% compared to RMB 454.37 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached approximately RMB 49.52 million, a year-on-year increase of 40.97% from RMB 35.13 million[20]. - The company reported a significant increase in employee compensation liabilities, rising to CNY 15,298,427.86 from CNY 3,519,655.11, reflecting potential growth in workforce or salary adjustments[126]. - The company reported a total profit of CNY 61,550,494.31 for the first half of 2020, compared to CNY 45,923,499.52 in the previous year, marking an increase of 34%[134]. - The company reported a net profit of ¥69,238,556.50 for the first half of 2020, compared to a net profit of ¥44,669,061.00 in the same period of 2019, indicating an increase of approximately 55.2%[133]. Research and Development - Research and development expenses increased by 30%, totaling 50 million CNY, focusing on innovative drug development[13]. - The company's R&D investment accounted for 7.96% of its operating revenue, an increase of 1.32 percentage points compared to 6.63% in the previous year[21]. - The company has established a product pipeline with 34 varieties and 53 drug approvals, including 3 innovative drugs and 2 modified new drugs under development[27]. - The company is actively advancing the development of anti-influenza drugs, with projects like the palivizumab inhalation solution in Phase I/II clinical trials and the new generation antiviral NX-2016 in preclinical research[52]. - The company has ongoing projects in the antiviral field, including the inhalation solution of Peramivir, which is currently in Phase I/II clinical trials[41]. - The company is developing Metafenin, a third-generation anti-tumor drug, which is currently in Phase Ib/IIa clinical trials[45]. - The company has a strong R&D team with expertise across various disciplines, enhancing its drug development capabilities[51]. Market Expansion and Strategy - The company plans to launch two new products in Q3 2020, aiming to capture an additional 10% market share in the pharmaceutical sector[13]. - The company is expanding its market presence in Southeast Asia, targeting a revenue contribution of 20% from this region by the end of 2021[13]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product pipeline and is projected to close by Q4 2020[13]. - The company has set a performance guidance for the full year 2020, aiming for a revenue growth of 20% compared to 2019[13]. Financial Position and Assets - The total assets of the company at the end of the reporting period were approximately RMB 1.95 billion, an increase of 138.41% compared to RMB 818.72 million at the end of the previous year[20]. - The company's net assets attributable to shareholders increased by 356.26%, reaching approximately RMB 1.52 billion[20]. - Cash and cash equivalents at the end of the period amounted to ¥1,116,942,003.53, representing 57.22% of total assets, a 450.39% increase from the previous year[70]. - The total assets as of June 30, 2020, were CNY 1,951,939,068.08, compared to CNY 818,717,329.92 at the end of 2019, indicating significant growth[126]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which could impact future performance[13]. - The company is exposed to risks related to the approval of new drug applications and potential competition from generic products[62]. - Future profitability may be impacted by royalty payments of 0.2% on domestic sales of Palivizumab sodium injection starting from 2028[63]. - The company faces risks from potential loss of core technical personnel and the leakage of core technologies[62]. Shareholder Commitments and Dividends - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profits for the year after legal reserves are deducted, with a cumulative distribution of at least 30% of the average annual distributable profits over the last three years post-IPO[85]. - The controlling shareholder committed to submit a stock buyback plan within 10 trading days if the stock price falls below the audited net asset value per share for 20 consecutive trading days[89]. - The company guarantees that cash distributions to shareholders from subsidiaries will not be less than 30% of the subsidiaries' distributable profits for the year[85]. Compliance and Governance - The company has committed to fulfilling all public commitments made during its IPO process and is open to social supervision[100]. - The company has not reported any significant changes in its accounting policies during the reporting period[158]. - The company follows the accounting policies in accordance with the requirements of the Chinese accounting standards[159]. Environmental and Quality Control - The company has established a strict pharmaceutical production quality management system to handle environmental pollutants generated during production, ensuring compliance with environmental regulations[107]. - The company has not experienced any major environmental pollution incidents during the reporting period and has adhered to national environmental laws and regulations[107]. Share Capital and Ownership - The total share capital increased from 105 million shares to 140 million shares after the issuance of 35 million new shares[111]. - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 40 million shares, representing 28.57% of the total shares[115]. - The number of shareholders reached 14,284 by the end of the reporting period[113].

Financial Performance - Operating revenue for the period was CNY 325,616,521.18, reflecting a growth of 39.89% compared to the same period last year[6] - Net profit attributable to shareholders increased by 28.22% to CNY 26,378,655.96 year-over-year[6] - Total operating revenue for Q1 2020 reached ¥325,616,521.18, a 39.8% increase from ¥232,767,051.46 in Q1 2019[28] - Net profit for Q1 2020 was ¥28,512,421.77, representing a 38.7% increase compared to ¥20,573,320.06 in Q1 2019[29] - Total profit for Q1 2020 was ¥34,505,344.74, up 34.2% from ¥25,716,650.08 in Q1 2019[28] - Total comprehensive income for Q1 2020 was CNY 15,096,347.65, compared to CNY 9,551,745.58 in Q1 2019, representing a year-over-year increase of approximately 58.5%[33] Assets and Liabilities - Total assets increased by 143.22% to CNY 1,991,252,498.15 compared to the end of the previous year[6] - Total liabilities amounted to ¥470,191,618.25, up from ¥461,451,171.79, indicating a rise in overall debt levels[23] - Current liabilities rose to ¥349,873,229.51 compared to ¥340,705,187.62, showing an increase in short-term financial obligations[22] - The company's total liabilities and equity reached ¥1,767,260,528.57, up from ¥590,376,152.39, showcasing overall financial growth[26] Shareholder Information - The total number of shareholders reached 19,261 by the end of the reporting period[10] - The top ten shareholders held a combined 85.00% of the company's shares, with the largest shareholder owning 28.57%[10] Cash Flow - The net cash flow from operating activities decreased by 90.35% to CNY 7,360,155.36 compared to the previous year[6] - Cash inflow from operating activities for Q1 2020 was CNY 336,025,280.86, compared to CNY 278,356,781.09 in Q1 2019, reflecting a growth of approximately 20.7%[34] - Cash outflow from operating activities totaled CNY 328,665,125.50 in Q1 2020, compared to CNY 202,118,473.59 in Q1 2019, which is an increase of about 62.5%[34] - Cash flow from financing activities showed a significant increase to CNY 1,143,043,149.56, compared to a negative cash flow of CNY 21,099,449.26 in the same period last year, reflecting successful fundraising efforts[12] Research and Development - Research and development expenses accounted for 6.75% of operating revenue, up from 5.98% in the previous year[6] - Research and development expenses increased by 57.96% to CNY 21,984,332.59 in Q1 2020, compared to CNY 13,917,686.16 in Q1 2019, indicating a focus on innovative drug development[12] - The company signed a technology development contract for the project "Oseltamivir Phosphate Dry Suspension" with a total R&D cost of CNY 30 million[13][15] - The company is advancing several new drug projects, including "Mefenamic Acid" for diabetic nephropathy and "Paxlovid" for influenza, with various stages of clinical trials ongoing[19] Earnings Per Share - Basic and diluted earnings per share were CNY 0.1884, down 3.83% from CNY 0.1959 in the previous year[6] - Basic earnings per share for Q1 2020 were ¥0.1884, slightly down from ¥0.1959 in Q1 2019[29]